3.3: Chemical Stability & Storage of Pharmaceuticals

3.3: Chemical Stability & Storage of Pharmaceuticals

Chemical Degradation Pathways

The chemical stability of a pharmaceutical product is defined as its ability to retain its chemical integrity and labeled potency within specified limits (usually $\ge 90%$ of initial concentration) throughout its shelf life. Understanding degradation pathways is essential for predicting incompatibilities, selecting appropriate packaging, and counseling patients on storage.

1. Hydrolysis

Hydrolysis is the cleavage of chemical bonds by water. It is the most common degradation pathway for drugs containing ester, amide, or lactam functional groups.

• Ester Hydrolysis: Esters are highly susceptible to nucleophilic attack by water or hydroxyl ions. A classic example is aspirin (acetylsalicylic acid), which hydrolyses into salicylic acid and acetic acid (imparting a vinegar-like odor).
• Amide and Lactam Hydrolysis: Lactams (cyclic amides) are highly strained rings prone to rapid hydrolysis. This is the primary degradation pathway for beta-lactam antibiotics (e.g., penicillins, cephalosporins), rendering them inactive.
• Stabilisation Strategies:
  • Formulating as a dry powder for reconstitution (e.g., amoxicillin suspension, which has a shelf life of only 7–14 days once reconstituted).
  • Controlling formulation pH to the point of minimum degradation (often between pH 5 and 6).
  • Replacing water with non-aqueous co-solvents (e.g., propylene glycol, ethanol in injections).
  • Using desiccants in packaging.

2. Oxidation

Oxidation involves the loss of electrons, addition of oxygen, or removal of hydrogen. It is typically mediated by a free-radical chain mechanism (auto-oxidation) involving initiation, propagation, and termination steps.

• Susceptible Groups: Molecules with phenolic hydroxyl groups (e.g., adrenaline/epinephrine, morphine, dopamine) or conjugated double bonds.
• Visual Indicators: Oxidation of adrenaline leads to the formation of adrenochrome, which turns the solution pink, then brown. Oxidised solutions must be discarded.
• Stabilisation Strategies:
  • Adding antioxidants: water-soluble reducing agents (e.g., sodium metabisulfite for acidic solutions, sodium bisulfite, ascorbic acid) or lipid-soluble chain-terminating agents (e.g., butylated hydroxytoluene [BHT], alpha-tocopherol).
  • Adding chelating agents (e.g., edetate disodium [EDTA]) to bind trace heavy metals ($Cu^{2+}, Fe^{3+}$) that catalyse free-radical initiation.
  • Purging container headspaces with inert gases (e.g., nitrogen).

3. Photolysis

Photolysis is the degradation of drug molecules by electromagnetic radiation (UV or visible light).

• Susceptible Drugs: Nifedipine, sodium nitroprusside, chlorpromazine, and riboflavin. Sodium nitroprusside infusion bags must be wrapped in light-resistant overwrap (e.g., aluminum foil) immediately upon preparation to prevent rapid degradation to toxic cyanide ions.
• Stabilisation Strategies: Use of amber glass containers (which block light wavelengths $< 470\text{ nm}$) and opaque secondary packaging.

---

Reaction Kinetics and Shelf Life Determination

Shelf life ($t_{90}$) is the time required for the drug concentration to degrade to 90% of its original concentration ($C_0$).

Zero-Order Kinetics

The rate of degradation is independent of the reactant concentration: $-\frac{dC}{dt} = k_0$ $C = C_0 - k_0 t$ $t_{90} = \frac{0.1 \cdot C_0}{k_0}$

• Application: Suspensions (where dissolved drug is continuously replenished by solid particles) and some topical formulations.

First-Order Kinetics

The rate of degradation is directly proportional to the concentration of the remaining drug: $-\frac{dC}{dt} = k C$ $\ln C = \ln C_0 - k t \quad \text{or} \quad C = C_0 e^{-k t}$ $t_{90} = \frac{-\ln(0.9)}{k} \approx \frac{0.105}{k}$

• Application: Most drug solutions and degradation processes.

Temperature Dependency and the Arrhenius Equation

The rate constant ($k$) is temperature-dependent and described by the Arrhenius equation: $k = A \cdot e^{-\frac{E_a}{R \cdot T}}$

ight) = -\frac{E_a}{R} \cdot \left(\frac{1}{T_2} - \frac{1}{T_1}\right)$$ Where $$E_a$$ is the activation energy, $$R$$ is the gas constant, and $$T$$ is the absolute temperature in Kelvin. #### The $$Q_{10}$$ Method for Shelf Life Estimation The $$Q_{10}$$ temperature coefficient is the factor by which the rate of degradation increases when the temperature is raised by 10°C. For many drugs, $$Q_{10}$$ is conservatively assumed to be 3 (or 2 for less temperature-sensitive reactions): $$t_{90}(T_2) = \frac{t_{90}(T_1)}{Q_{10}^{\frac{\Delta T}{10}}}$$ *Worked Example:* A reconstituted antibiotic has a shelf life of 14 days when stored in the refrigerator (5°C). If stored at room temperature (25°C), estimate its shelf life assuming $$Q_{10} = 3$$. 1. Calculate $$\Delta T$$: $$\Delta T = 25^\circ\text{C} - 5^\circ\text{C} = 20^\circ\text{C}$$ 2. Apply the $$Q_{10}$$ formula: $$t_{90}(25^\circ\text{C}) = \frac{14\text{ days}}{3^{\frac{20}{10}}} = \frac{14}{3^2} = \frac{14}{9} \approx 1.55\text{ days (approx. 37 hours)}$$ --- ## Role of Preservatives and Packaging Materials ### Preservatives Multi-dose preparations require antimicrobial preservatives to prevent microbial proliferation introduced during repeated use. * **Benzalkonium chloride (BAC):** Commonly used in eye drops. It can cause corneal cell damage with chronic use and is absorbed by soft contact lenses; lenses must be removed before instillation and left out for at least 15 minutes. * **Parabens (Methyl/Propylparaben):** Used in oral solutions and topicals. * **Benzyl Alcohol:** Used in multi-dose parenterals. **Clinical Contraindication:** Contraindicated in neonates and premature infants. Neonates lack mature glycine conjugation pathways in the liver, leading to the accumulation of benzoic acid, causing metabolic acidosis and respiratory collapse ("gasping syndrome"). ### Packaging Materials * **Glass Containers:** Classified by chemical resistance: * *Type I (Borosilicate glass):* High hydrolytic resistance. Used for sterile parenterals. * *Type II (Treated soda-lime glass):* De-alkalised surface. Used for acidic/neutral parenterals. * *Type III (Soda-lime glass):* Moderate resistance. Used for non-aqueous parenterals and dry powders. * **Plastics and PVC:** * **Sorption:** Sorption includes adsorption (surface binding) and absorption (penetration into the plastic matrix). Lipophilic drugs (e.g., nitroglycerin, diazepam, insulin, amiodarone) readily undergo sorption to polyvinyl chloride (PVC) bags and administration sets. They must be prepared in non-PVC containers (e.g., polyolefin, polyethylene, or glass) and administered using low-sorbing tubing. * **Leaching:** Plasticisers like DEHP (di-2-ethylhexyl phthalate) can leach from PVC into lipophilic solutions (e.g., taxane chemotherapy infusions). --- ## Cold Chain Storage and Australian Guidelines ("Strive for 5") In Australia, the National Vaccine Storage Guidelines ("Strive for 5") outline strict protocols for managing cold chain products (primarily vaccines, insulins, and biologicals) which must be stored between **2°C and 8°C**. ### Handling Temperature Breaches A cold chain breach occurs if storage temperatures go outside the 2°C to 8°C range (excluding brief fluctuations up to 12°C lasting less than 15 minutes during stock management). If a breach is identified: 1. **Isolate:** Do not discard vaccines. Immediately isolate them in a functioning refrigerator or cold transport container between 2°C and 8°C. 2. **Label:** Clearly label the stock "DO NOT USE - KEEP REFRIGERATED" to prevent accidental administration. 3. **Document:** Record the duration of the breach, the minimum/maximum temperatures reached, and the inventory affected. 4. **Contact:** Report the breach to the local state or territory health department (for government-funded vaccines) or the manufacturer (for private stock) to obtain stability data. Do not use or discard the stock until written advice is received. 5. **Freeze Warning:** Vaccines containing aluminum adjuvants (e.g., DTPa, HepB) must never be frozen. Freezing causes irreversible aggregation of the adjuvant, destroying vaccine potency and increasing the risk of sterile abscesses at the injection site.